Caregen 
Welcome,         Profile    Billing    Logout  
  Products    Diseases   Products    Trials    News 
1 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
CG-SpikeDown / Caregen
NCT05234320: Study to Evaluate the Safety, Tolerability, and Pharmacokinetics in Healthy Volunteers of the Novel Self-Administered Intranasal CG- SpikeDown Antiviral Drug

Not yet recruiting
1
16
NA
CG-SpikeDown, intranasal formulation, Vehicle (Placebo), Standard of core (type of therapy is depend of decide of the site)
Caregen Co. Ltd.
Healthy
01/23
01/23
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
CG-SpikeDown / Caregen
NCT05234320: Study to Evaluate the Safety, Tolerability, and Pharmacokinetics in Healthy Volunteers of the Novel Self-Administered Intranasal CG- SpikeDown Antiviral Drug

Not yet recruiting
1
16
NA
CG-SpikeDown, intranasal formulation, Vehicle (Placebo), Standard of core (type of therapy is depend of decide of the site)
Caregen Co. Ltd.
Healthy
01/23
01/23

Download Options